A phase II trial of imatinib mesylate (Gleevec®) in myeloproliferative disorders other than CML.

被引：0
|
作者：
Kuriakose, P
Shurafa, MS
机构：
[1] Henry Ford Hosp, Div Hematol Oncol, Detroit, MI 48202 USA
[2] Van Elslander Canc Ctr, Grosse Pointe Woods, MI USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4765
引用
收藏
页码：274B / 274B
页数：1
相关论文
共 50 条
  • [1] The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML.
    O'Dwyer, ME
    Mauro, MJ
    Kurilik, G
    Balleisen, S
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 139A - 139A
  • [2] The mechanism of geldanamycin compared with imatinib mesylate in CML.
    Sato, E
    Sugimoto, K
    Oshimi, K
    BLOOD, 2003, 102 (11) : 324B - 325B
  • [3] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML.
    O'Dwyer, ME
    Mauro, MJ
    Kuyl, JM
    Paquette, R
    Sawyers, CL
    Druker, BJ
    BLOOD, 2001, 98 (11) : 846A - 846A
  • [4] Imatinib mesylate (Gleevec®) for patients with chronic idiopathic myelofibrosis (CIM):: A phase II trial
    De Angelo, DJ
    Soiffer, RJ
    Galinisky, I
    Clark, JJ
    Gilliland, DG
    Shanahan, J
    Amrein, PC
    Stone, RM
    BLOOD, 2003, 102 (11) : 146A - 146A
  • [5] Phase II trial of imatinib mesylate (GLEEVEC) and hydroxyurea for adults with recurrent/progressive meningioma
    Goli, Krishna
    Bota, Daniela
    Desjardins, Annick
    Rich, Jeremy
    Vredenburgh, James
    Quinn, Jennifer
    Sathornsumetee, Sith
    Salvado, August
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 519 - 519
  • [6] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML.
    Mauro, MJ
    O'Dwyer, ME
    Stone, RM
    Walker, T
    Wiese, A
    Druker, BJ
    BLOOD, 2002, 100 (11) : 165A - 165A
  • [7] Abnormal cytogenetic evolution in a case of CML treated by imatinib mesylate (Gleevec®).
    Besalduch, J
    Gutierrez, A
    Rosell, J
    Bernues, M
    Sampol, A
    BLOOD, 2002, 100 (11) : 331B - 331B
  • [8] A prospective analysis of the consequences of imatinib mesylate inhibition of sensitive kinases other than BCR-ABL in patients with previously untreated early chronic phase CML.
    Seymour, JF
    Grigg, AP
    Matthews, J
    Taylor, K
    Guzzo-Pernell, N
    Mills, AK
    Lynch, K
    Hughes, TP
    BLOOD, 2003, 102 (11) : 911A - 911A
  • [9] Pancytopenia, a complication of Gleevec in treatment of accelerated and chronic phase CML.
    Zalzaleh, G
    Jajeh, A
    BLOOD, 2003, 102 (11) : 310B - 310B
  • [10] Imatinib mesylate (STI571) for myeloid malignancies other than CML
    Krystal, GW
    LEUKEMIA RESEARCH, 2004, 28 : S53 - S59
12345